Yan Yuerong, Hu Fengqiu, Wu Weilu, Ma Ruiting, Huang Hui
Department of Endocrinology and Metabolism Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Medicine (Baltimore). 2017 Mar;96(12):e6393. doi: 10.1097/MD.0000000000006393.
Type 2 diabetes mellitus (T2DM) is related to increased risk of papillary thyroid carcinoma (PTC). Insulin-like growth factor-1 receptor (IGF-1R) is increased in patients with T2DM. The increased IGF-1R may be responsible for the development of PTC. In this study, we investigated the expression of phosphorylation of Akt (p-Akt)/survivin pathway activated by IGF-1R in PTC subjects with and without diabetes.Clinicopathological data of 20 PTC patients with T2DM were retrospectively analyzed and compared with those of 21 PTC subjects without diabetes. Meanwhile, IGF-1R, p-Akt, and survivin expressions of PTC tissues were detected by immunohistochemical staining.The immunohistochemical results found that the expression level of IGF-1R was significantly higher in diabetic PTC patients than that in nondiabetic PTC patients (P < 0.05). However, no significant differences of p-Akt and survivin expression were found between PTC patients with T2DM and PTC patients without T2DM. In addition, among 20 PTC patients with T2DM, subgroup analysis showed that the ratio of tumor size >10 mm was significantly higher in IGF-1R moderate to strong expression group than that in IGF-1R negative to weak expression group (P < 0.05).IGF-1R expression level was higher in PTC patients with T2DM, and the increased IGF-1R expression was associated with lager tumor size. IGF-1R may play an important role in carcinogenesis and tumor growth in PTC patients with T2DM.
2型糖尿病(T2DM)与甲状腺乳头状癌(PTC)风险增加相关。T2DM患者的胰岛素样生长因子-1受体(IGF-1R)水平升高。IGF-1R升高可能是PTC发生的原因。在本研究中,我们调查了IGF-1R激活的Akt磷酸化(p-Akt)/生存素通路在合并或未合并糖尿病的PTC患者中的表达情况。对20例合并T2DM的PTC患者的临床病理资料进行回顾性分析,并与21例未患糖尿病的PTC患者进行比较。同时,采用免疫组织化学染色检测PTC组织中IGF-1R、p-Akt和生存素的表达。免疫组织化学结果显示,糖尿病PTC患者的IGF-1R表达水平显著高于非糖尿病PTC患者(P<0.05)。然而,合并T2DM的PTC患者与未合并T2DM的PTC患者之间,p-Akt和生存素表达无显著差异。此外,在20例合并T2DM的PTC患者中,亚组分析显示,IGF-1R中度至强表达组肿瘤大小>10mm的比例显著高于IGF-1R阴性至弱表达组(P<0.05)。合并T2DM的PTC患者的IGF-1R表达水平较高,且IGF-1R表达增加与肿瘤较大有关。IGF-1R可能在合并T2DM的PTC患者的致癌作用和肿瘤生长中起重要作用。